PREASSEMBLED, PREFILLED SYRINGES1*
REBIJECT II® AUTOINJECTOR2*
REBIF® REBIDOSE® (INTERFERON BETA-1A)3*
*Images shown are not actual size.
Rebif® allows you to adjust the dose to meet individual patient needs without changing therapy.1
PRISMS was not designed to determine differences in efficacy between the 22 mcg and 44 mcg-dose groups. Both doses were shown to be effective vs placebo in the treatment of patients with relapsing forms of MS.‡ The type of adverse events reported for 22 mcg was the same as for 44 mcg and includes, most commonly, flu-like symptoms and injection-site reactions. The incidence of leukopenia and elevated liver function tests observed was lower in patients receiving 22 mcg 3 times weekly.4
†Injections should be taken 3 times weekly and at least 48 hours apart.
‡Mean number of relapses at 2 years was 1.73 and 1.82 for Rebif® 44 mcg and 22 mcg, respectively, vs 2.56 with placebo.
Rebif® should be stored in the refrigerator between 36°F and 46°F (2°C and 8°C). DO NOT FREEZE. If a refrigerator is not available, Rebif® may be stored between 36°F and 77°F (2°C and 25°C) for up to 30 days and away from heat and light.
IMPORTANT SAFETY INFORMATION AND INDICATION
Important Safety Information
Rebif is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta, human albumin, or any other component of the formulation.
Rebif should be used with caution in patients with depression, a condition that is common in people with multiple sclerosis. Depression, suicidal ideation, and suicide attempts have been reported to occur with increased frequency in patients receiving interferon compounds, including Rebif.
Severe liver injury, including some cases of hepatic failure requiring liver transplantation, has been reported rarely in patients taking Rebif. The potential for liver injury should be considered when used in combination with other products associated with liver injury. Monitor liver function tests and patients for signs and symptoms of hepatic injury. Consider discontinuing Rebif if hepatic injury occurs.
Anaphylaxis and other allergic reactions (some severe) have been reported as a rare complication of Rebif. Discontinue Rebif if anaphylaxis occurs.
In controlled clinical trials, injection site reactions occurred more frequently in Rebif-treated patients than in placebo-treated and Avonex-treated patients. Injection site reactions including injection site pain, erythema, edema, cellulitis, abscess, and necrosis have been reported in the postmarketing setting. Do not administer Rebif into affected area until fully healed; if multiple lesions occur, discontinue Rebif until skin lesions are healed.
Decreased peripheral blood counts in all cell lines, including pancytopenia, have been reported in Rebif-treated patients. In controlled clinical trials, leukopenia occurred at a higher frequency in Rebif-treated patients than in placebo and Avonex-treated patients. Thrombocytopenia and anemia occurred more frequently in 44 mcg Rebif-treated patients than in placebo-treated patients. Patients should be monitored for symptoms or signs of decreased blood counts. Monitoring of complete blood and differential white blood cell counts is also recommended.
Cases of thrombotic microangiopathy (TMA), some fatal, have been reported with interferon beta products, including Rebif, up to several weeks or years after starting therapy. Discontinue Rebif if clinical symptoms and laboratory findings consistent with TMA occur, and manage as clinically indicated.
Caution should be exercised when administering Rebif to patients with pre-existing seizure disorders. Seizures have been temporally associated with the use of beta interferons, including Rebif, in clinical trials and in postmarketing reports.
The most common side effects with Rebif are injection-site disorders, headaches, influenza-like symptoms, abdominal pain, depression, elevated liver enzymes, and hematologic abnormalities.
Epidemiological data do not suggest a clear relationship between interferon beta use and major congenital malformations, but interferon beta may cause fetal harm based on animal studies. Data from a large human population-based cohort study, as well as other published studies over several decades, have not identified a drug-associated risk of major birth defects with interferon beta products during early pregnancy. Findings regarding a potential risk for low birth weight or miscarriage with the use of interferon beta products in pregnancy have been inconsistent.
Rebif is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
References: 1. Rebif® [Prescribing Information]. Rockland, MA: EMD Serono, Inc. 2. Rebiject II [Instructions for Use]. Rockland, MA: EMD Serono, Inc. 3. Rebif® Rebidose® [Instructions for Use]. Rockland, MA: EMD Serono, Inc. 4. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352(9139):1498-1504.